Cyclacel Pharmaceuticals, Inc. (CYCC): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el mundo de vanguardia de la investigación de oncología, Cyclacel Pharmaceuticals, Inc. (CYCC) emerge como una fuerza pionera, navegando estratégicamente el complejo paisaje de la terapéutica del cáncer dirigido. Al aprovechar un modelo de negocio sofisticado que entrea en investigación innovadora, asociaciones estratégicas y enfoques de medicina de precisión, la compañía está a la vanguardia de tratamientos de cáncer potencialmente transformadores. Su proposición de valor única se centra en el desarrollo de nuevas terapias dirigidas al ciclo celular que prometen revolucionar cómo entendemos y combatemos los tipos de cáncer desafiantes, lo que hace que su modelo de negocio sea una exploración fascinante del emprendimiento científico y la innovación médica.

Cyclacel Pharmaceuticals, Inc. (CYCC) - Modelo de negocio: asociaciones clave

Colaboraciones con instituciones de investigación académica

A partir de 2024, Cyclacel Pharmaceuticals mantiene colaboraciones de investigación con:

Institución	Enfoque de investigación	Estado de colaboración
Universidad de Glasgow	Investigación terapéutica del cáncer	Asociación activa
Universidad de Stanford	Estudios de oncología molecular	Acuerdo de investigación en curso

Alianzas estratégicas con socios de desarrollo farmacéutico

Las asociaciones estratégicas de desarrollo farmacéutico de Cyclacel incluyen:

• Servier Laboratories (Francia)
• Nucana PLC (Reino Unido)
• Yakult Honsha Co., Ltd. (Japón)

Posibles acuerdos de licencia para candidatos a drogas

Candidato a la droga	Licenciatario	Valor estimado
CYC065	Negociaciones pendientes	$ 12.5 millones de pago inicial potencial
CYC140	Bajo evaluación	Pagos potenciales de $ 8.3 millones

Organizaciones de investigación por contrato para ensayos clínicos

Asociaciones de ensayos clínicos activos de Cyclacel:

• Parexel International Corporation
• Ícono plc
• IQVIA Holdings Inc.

Cro	Fase de ensayo clínico	Valor de contrato
Parexel	Ensayos de oncología de fase II	$ 4.2 millones
ICONO	Estudios de fase I/II	$ 3.7 millones

Cyclacel Pharmaceuticals, Inc. (CYCC) - Modelo de negocio: actividades clave

Investigación y desarrollo de drogas oncológicas

A partir del cuarto trimestre de 2023, los productos farmacéuticos de Ciclacel se centraron en desarrollar Terapias de cáncer dirigidas.

Área de investigación	Inversión	Enfocar
Terapéutica del ciclo celular	Gastos de I + D de $ 6.2 millones (2023)	Tratamientos de oncología de precisión
Orientación molecular	Presupuesto de investigación de $ 4.8 millones	Desarrollo del inhibidor de CDK

Gestión de ensayos clínicos

Cartera de ensayos clínicos activos con áreas de enfoque específicas:

• Ensayos de fase 2/3 para el programa clínico CYC140
• Estudios en curso en leucemia mieloide aguda (AML)
• Presupuesto de ensayos clínicos: $ 3.5 millones (2023)

Procesos de presentación y aprobación regulatoria

Actividad regulatoria	Estado	Inversión
Interacción de la FDA	Comunicación continua	Costos de cumplimiento regulatorio de $ 750,000
Aplicaciones de IN	Múltiples presentaciones activas	$ 450,000 Preparación regulatoria

Protección de propiedad intelectual

Estrategia de gestión de cartera de patentes:

• 8 familias de patentes activas
• Costos de mantenimiento de patentes: $ 620,000 anualmente
• Protección de propiedad intelectual en múltiples jurisdicciones

Desarrollo de productos farmacéuticos

Producto	Etapa de desarrollo	Costo de desarrollo estimado
CYC140	Ensayos clínicos de fase 2	$ 5.6 millones
Candidatos preclínicos	Investigación en etapa inicial	$ 2.3 millones

Cyclacel Pharmaceuticals, Inc. (CYCC) - Modelo de negocio: recursos clave

Experiencia de investigación de oncología especializada

A partir de 2024, Cyclacel mantiene un equipo de investigación de oncología enfocada con 12 investigadores científicos dedicados. La compañía ha acumulado más de 20 años de experiencia especializada en investigación de terapia contra el cáncer.

Categoría de investigación	Número de investigadores	Años de experiencia
Especialistas en oncología	12	20+

Portafolio de patentes para terapias para el cáncer dirigidos

Ciclacel tiene 7 patentes activas relacionado con las terapias de cáncer dirigidas a partir de 2024.

Tipo de patente	Número de patentes	Estado de patente
Tecnologías de terapia del cáncer	7	Activo

Instalaciones de investigación científica

La compañía opera un Laboratorio de investigación de 3,500 pies cuadrados Ubicado en Berkeley, California, equipado con infraestructura avanzada de biología molecular e investigación del cáncer.

Equipo de gestión y científico experimentado

• Total de empleados: 25
• Titulares de doctorado: 15
• Experiencia de investigación promedio: 12 años

Tecnologías de desarrollo de fármacos patentados

Ciclacel se ha desarrollado 2 plataformas de desarrollo de fármacos patentados centrado en las tecnologías de respuesta al ciclo celular y el daño por ADN.

Plataforma tecnológica	Estado de desarrollo	Enfoque terapéutico
Plataforma de orientación del ciclo celular	Desarrollado	Terapias contra el cáncer
Plataforma de respuesta de daño de ADN	Desarrollado	Terapias contra el cáncer

Cyclacel Pharmaceuticals, Inc. (CYCC) - Modelo de negocio: propuestas de valor

Terapéutica innovadora del cáncer dirigido

Ciclacel Pharmaceuticals se centra en el desarrollo Terapias contra el cáncer dirigidas al ciclo celular. A partir del cuarto trimestre de 2023, la compañía tiene ensayos clínicos en curso para Cyc065, un inhibidor de quinasa dependiente de ciclina (CDK).

Candidato a la droga	Indicación objetivo	Estadio clínico
CYC065	Tumores sólidos avanzados	Ensayo clínico de fase 1/2
Sapacitabina	Leucemia mieloide aguda	Desarrollo clínico avanzado

Posibles tratamientos innovadores para cánceres difíciles de tratar

La tubería de investigación de la compañía se dirige a tipos de cáncer desafiantes con opciones de tratamiento limitadas.

• Centrarse en las neoplasias hematológicas
• Tratamientos potenciales para pacientes de edad avanzada con leucemia mieloide aguda
• Enfoques innovadores para pacientes con cáncer recidivante/refractario

Enfoque de medicina de precisión a la oncología

Ciclacel utiliza Estrategias de orientación molecular para desarrollar tratamientos de cáncer más precisos.

Enfoque de medicina de precisión	Características clave
Orientación molecular	Mecanismos celulares específicos
Perfil genético	Selección de tratamiento específica del paciente

Desarrollo de fármacos con ciclo celular novedoso

A partir de 2023, Cyclacel ha invertido $ 12.4 millones en investigación y desarrollo para la terapéutica dirigida al ciclo celular.

• Tecnología de inhibidores de CDK patentado
• Mecanismo único de acción en el tratamiento del cáncer
• Potencial para reducir los efectos secundarios en comparación con la quimioterapia tradicional

Mejoras potenciales en los resultados del tratamiento del paciente

La capitalización de mercado de Cyclacel a partir de enero de 2024 es de aproximadamente $ 14.5 millones, lo que refleja el potencial de su enfoque innovador.

Métrica de resultados del tratamiento	Mejora potencial
Tasas de supervivencia del paciente	El enfoque dirigido puede extender la supervivencia
Calidad de vida	Potencial de efectos secundarios reducidos

Cyclacel Pharmaceuticals, Inc. (CYCC) - Modelo comercial: relaciones con los clientes

Compromiso directo con profesionales médicos

A partir del cuarto trimestre de 2023, Cyclacel mantiene canales de comunicación directa con especialistas en oncología y hematólogos a través de programas de divulgación específicos.

Método de compromiso	Frecuencia	Público objetivo
Consultas individuales	Trimestral	Especialistas en oncología
Plataformas de comunicación digital	Mensual	Médicos de investigación

Conferencias científicas e interacciones comunitarias de investigación

Cyclacel participa en conferencias clave de investigación oncológica para mantener la credibilidad científica y las relaciones profesionales.

• Conferencia anual de la Asociación Americana de Investigación del Cáncer (AACR)
• Reunión anual de la Asociación Europea de Hematología (EHA)
• Conferencia anual de la Sociedad Americana de Oncología Clínica (ASCO)

Programas de apoyo al paciente

La Compañía implementa iniciativas de apoyo al paciente dirigidas para los participantes de los ensayos clínicos y los posibles receptores de tratamiento.

Programa de apoyo	Cobertura	Accesibilidad
Soporte de paciente de ensayo clínico	Atención integral del paciente	Coordinación directa del equipo médico
Recursos de información del tratamiento	Materiales en línea e impresos	Acceso digital 24/7

Comunicación transparente sobre el progreso del ensayo clínico

Ciclacel mantiene Protocolos de comunicación rigurosos para actualizaciones de ensayos clínicos.

• Informes de progreso de ensayos clínicos trimestrales
• Presentaciones de inversores y partes interesadas
• SEC presentando actualizaciones

Iniciativas de educación médica y concientización

La compañía invierte en programas de educación profesional médica que se centran en tratamientos de oncología específicos.

Plataforma educativa	Grupo objetivo	Frecuencia
Serie de seminarios web	Investigadores de oncología	Bimensual
Apoyo de publicación científica	Instituciones académicas	En curso

Cyclacel Pharmaceuticals, Inc. (CYCC) - Modelo de negocio: canales

Ventas directas a instituciones de atención médica

A partir del cuarto trimestre de 2023, Cyclacel mantiene canales de ventas directos dirigidos a los departamentos de oncología en centros de tratamiento de cáncer especializados.

Tipo de canal	Instituciones objetivo	Enfoque especializado
Ventas de oncología directa	Centros de cáncer integrales	Investigación de neoplasias hematológicas
Distribución farmacéutica	Centros médicos académicos	Atención de apoyo de ensayo clínico

Presentaciones de conferencia médica

Cyclacel utiliza conferencias médicas especializadas para la comunicación del producto y la validación científica.

• Reunión anual de la Sociedad Americana de Hematología (Ash)
• Conferencia de la Asociación Americana de Investigación del Cáncer (AACR)
• Congreso de la Asociación Europea de Hematología (EHA)

Publicaciones científicas

Los canales de publicación científica sirven como plataformas de comunicación crítica para la validación de la investigación.

Tipo de publicación	Revistas revisadas por pares	Frecuencia de publicación (2023)
Artículos de investigación	Diario de sangre	3 publicaciones
Resultados del ensayo clínico	Revista de oncología clínica	2 publicaciones

Redes de la industria farmacéutica

Canales de asociación estratégica Habilitar iniciativas más amplias de penetración del mercado e investigación de colaboración.

• Red de la Organización de Innovación de Biotecnología (BIO)
• Investigación farmacéutica y fabricantes de América (phrma)
• Colaboraciones estratégicas internacionales

Comunicaciones de relaciones con los inversores

Los canales de comunicación de los inversores proporcionan transparencia y participación del mercado.

Plataforma de comunicación	Frecuencia	Alcance de los inversores
Llamadas de ganancias trimestrales	4 veces anualmente	Aproximadamente 150 inversores institucionales
Reunión anual de accionistas	1 vez anualmente	Base de inversores que cotiza en la lista de NASDAQ

Cyclacel Pharmaceuticals, Inc. (CYCC) - Modelo de negocio: segmentos de clientes

Profesionales de la salud oncológica

El ciclacel se dirige a especialistas en oncología con enfoque específico en neoplasias hematológicas y profesionales del tratamiento del cáncer.

Característica de segmento	Datos detallados
Especialistas en oncología objetivo	Aproximadamente 15,000 especialistas en hematología/oncología en los Estados Unidos
Tasa de compromiso anual	Estimado del 37% de los especialistas objetivo involucrados con la investigación de la compañía

Centros de tratamiento del cáncer

Centros de cáncer integrales que representan a los clientes institucionales primarios.

Tipo de centro de tratamiento	Número de clientes potenciales
Centros de cáncer integrales designados por NCI	51 centros en todo el país
Centros de cáncer comunitario	Más de 1.500 clientes institucionales potenciales

Investigar hospitales

Instituciones médicas académicas y centradas en la investigación interesadas en tratamientos avanzados de oncología.

• Hospitales de investigación de primer nivel: 38 instituciones principales
• Presupuesto de colaboración de investigación anual: $ 12.5 millones
• Sitios potenciales de ensayos clínicos: 24 hospitales de investigación líderes

Distribuidores farmacéuticos

Canales de distribución para posibles productos farmacéuticos.

Categoría de distribuidor	Penetración del mercado
Distribuidores farmacéuticos nacionales	3 distribuidores principales
Distribuidores especializados regionales	12 redes de distribución especializadas

Pacientes con tipos de cáncer específicos

Poblaciones de pacientes dirigidas para tratamientos especializados.

Tipo de cáncer	Población de pacientes estimada
Leucemia mieloide aguda (AML)	20,530 casos nuevos anualmente
Síndrome de mielodisplásico (MDS)	10,200 casos nuevos anualmente

Cyclacel Pharmaceuticals, Inc. (CYCC) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal que finalizó el 31 de diciembre de 2022, Ciclacel Pharmaceuticals reportó gastos de I + D de $ 13.1 millones.

Año	Gastos de I + D ($)
2022	13,100,000
2021	15,300,000

Inversiones de ensayos clínicos

Los costos de ensayos clínicos para el ciclacel en 2022 fueron de aproximadamente $ 8.7 millones, centrándose en desarrollos terapéuticos oncológicos.

• Enfoque primario: ensayos clínicos de fadraciclib
• Fase 2 Inversiones de ensayos clínicos: $ 5.2 millones
• Programas de investigación clínica en curso: $ 3.5 millones

Costos de cumplimiento regulatorio

Los gastos de cumplimiento regulatorio para 2022 se estimaron en $ 1.5 millones.

Mantenimiento de la propiedad intelectual

La propiedad intelectual y los gastos relacionados con la patente totalizaron $ 650,000 en 2022.

Categoría de IP	Costo ($)
Presentación de patentes	450,000
Mantenimiento de patentes	200,000

Sobrecarga administrativa y operativa

La sobrecarga administrativa y operativa total para 2022 fue de $ 6.3 millones.

• Gastos administrativos generales: $ 4.2 millones
• Costos de soporte operativo: $ 2.1 millones

Cyclacel Pharmaceuticals, Inc. (CYCC) - Modelo comercial: flujos de ingresos

Ingresos potenciales de licencia de medicamentos futuros

A partir del cuarto trimestre de 2023, los posibles ingresos por licencias de medicamentos de Cyclacel se asocian principalmente con sus compuestos de etapa clínica Cyc140 y Cyc065. La estrategia de licencia de la compañía se dirige a posibles ingresos de:

• Acuerdos de licencia mundiales para terapéutica de oncología dirigida
• Pagos potenciales de hitos de socios farmacéuticos
• Estructuras de regalías para futuras comercialización

Subvenciones de investigación

Cyclacel ha recibido históricamente subvenciones de investigación de varias fuentes. Los datos financieros más recientes indican ingresos por subvenciones de investigación de aproximadamente $ 0.5 millones para el año fiscal 2022.

Fuente de subvenciones	Cantidad (USD)	Año
Institutos Nacionales de Salud (NIH)	$350,000	2022
Otras instituciones de investigación	$150,000	2022

Financiación de la investigación colaborativa

La financiación de la investigación colaborativa representa un flujo de ingresos crítico para el ciclacel. A partir de 2023, la compañía ha mantenido asociaciones estratégicas con:

• Instituciones de investigación académica
• Organizaciones de desarrollo farmacéutico
• Redes de investigación oncológica

Venta potencial de productos farmacéuticos

Si bien el ciclacel actualmente no tiene productos comerciales aprobados por la FDA, las posibles ventas de productos farmacéuticos futuros se anticipan de:

• Desarrollo clínico CYC140
• Comercialización terapéutica oncológica potencial
• Estrategias de orientación de medicina de precisión

Pagos de hitos de asociaciones estratégicas

Los pagos de hitos de asociación estratégica son un componente de ingresos potencial clave. Los informes financieros de la Compañía indican posibles estructuras de pago de hitos que van desde $ 1 millón a $ 10 millones por etapa de desarrollo.

Etapa hito	Rango de pago potencial (USD)
Desarrollo preclínico	$ 1-3 millones
Ensayos clínicos de fase I	$ 3-5 millones
Ensayos clínicos de fase II	$ 5-10 millones

Cyclacel Pharmaceuticals, Inc. (CYCC) - Canvas Business Model: Value Propositions

The Value Propositions for Cyclacel Pharmaceuticals, Inc. as of late 2025 are centered on a highly focused oncology candidate and a newly acquired, non-core business segment.

Novel cancer treatment targeting cell cycle and mitosis biology

The core biopharmaceutical value proposition remains the development of innovative cancer medicines based on cell cycle and mitosis biology, specifically through the PLK1 inhibitor, plogosertib.

• Plogosertib is currently in Phase II clinical development for Leukemia.
• Initial dose escalation data from a Phase 1 clinical study of oral plogosertib showed the compound was well tolerated with no dose limiting toxicity observed across five dosing schedules.
• Clinical benefit was observed in patients with adenoid cystic, biliary tract, ovarian, and squamous cell sinus cancers.
• Preclinical data supports efficacy in certain ARID1A- and/or SMARCA-mutated cancers, and cancers associated with DNAJ-PKAc fusions.
• PLK1 inhibition is suggested to be effective in KRAS-mutated metastatic colorectal cancer based on recent data.

The financial commitment to this program reflects a sharp narrowing of focus following the liquidation of the UK subsidiary, Cyclacel Limited, on January 24, 2025.

Metric	Three Months Ended June 30, 2024	Three Months Ended June 30, 2025
Research and Development Expenses	$2.0 million	$0.1 million
UK R&D Tax Credits	$0.4 million	$0.0 million

Improved bioavailability via a new oral plogosertib formulation

A specific value-add within the plogosertib program is the ongoing effort to develop an alternative salt, oral formulation designed for improved bioavailability.

This development work is now the primary remaining focus of the R&D expenditure.

Essential fire protection products and services via the new division

Cyclacel Pharmaceuticals, Inc. has entered a strategic agreement to acquire Fitters Sdn. Bhd., a Malaysia-based private limited company specializing in supplying and trading various protective and fire safety equipment.

• The acquisition involves the issuance of approximately 19.99% of Cyclacel Pharmaceuticals, Inc.'s common stock to FITTERS Diversified Berhad.
• This move represents a pivot away from the historical biopharmaceutical identity, as indicated by the company analyzing strategic alternatives due to funding challenges.

The financial structure of the company as of June 30, 2025, showed cash and cash equivalents of $4.3 million, with management estimating this would fund planned expenditure only into the fourth quarter of 2025.

Cyclacel Pharmaceuticals, Inc. (CYCC) - Canvas Business Model: Customer Relationships

You're analyzing the relationships Cyclacel Pharmaceuticals, Inc. maintains across its capital structure and operational footprint as of late 2025. For a clinical-stage biotech, these relationships are critical for funding and trial execution. Honestly, the focus has clearly shifted post-subsidiary liquidation, which impacts how they interact with different stakeholders.

Direct, High-Touch Relationships with Key Investors and Shareholders

The relationship with the shareholder base is dynamic, marked by significant corporate actions in 2025 designed to maintain market listing and secure capital. The structure of ownership shows a heavy reliance on individuals, but key institutional moves are notable.

Here's a snapshot of the shareholder landscape and recent engagement:

Metric	Value/Detail	Date/Period Reference
Individual Shareholder Percentage	55.38%	Recent Filing (Pre-Sept 2025)
Fitters Diversified Bhd. Ownership	5.7%	Recent Filing (Pre-Sept 2025)
Authorized Common Stock Increase	From 100 million to 250 million shares	Effective February 10, 2025
Series D Preferred Stock Issued to David Lazar	2.1 million shares	February 2025
Institutional Investors Adding Shares (Q1 2025)	9 investors	Q1 2025
Largest Single Institutional Addition (Q1 2025)	ARMISTICE CAPITAL, LLC added 1,269,485 shares	Q1 2025

Shareholders demonstrated strong alignment in September 2025, approving key proposals where directors received at least 99.97% of the votes cast. You see, maintaining this level of support is vital when you're making structural changes.

Professional Engagement with Clinical Investigators and Trial Sites

Engagement here is highly professional and focused, driven by the need to execute the streamlined drug development plan centered on plogosertib. The company is acutely aware of the competitive environment for site access and investigator time.

• Focus shifted exclusively to the plogosertib clinical program after the UK subsidiary liquidation on January 24, 2025.
• As of November 24, 2025, there are ongoing clinical trials, including NCT05358379 for CYC140 (PLK1 Inhibitor).
• The target recruitment count for trial NCT05358379 is 330 subjects.
• The company acknowledges that the limited number of qualified clinical investigators means they may use sites competitors use, which reduces available patient pools.

Standard B2B/B2C Transactional Relationships for Fire Safety Products

This relationship stream is a direct result of a strategic transaction, not the core biopharma business. In Q1 2025, Cyclacel entered an agreement to acquire Fitters Sdn. Bhd., a Malaysia-based private limited company. This entity specializes in supplying and trading various protective and fire safety equipment. The transactional relationships for these products are managed by this newly integrated segment, which is distinct from the drug development pipeline.

Investor Relations for Public Market Transparency and Financing

Investor relations is the formal channel for communicating the financial narrative, especially following capital raises and corporate restructuring. Transparency is key, given the micro-cap status and recent volatility.

• Cash and cash equivalents stood at $4.3 million as of June 30, 2025.
• The company raised $3 million through a securities purchase agreement in Q2 2025.
• Quarterly cash dividends of $0.15 per share were declared on the 6% Convertible Exchangeable Preferred Stock in April 2025.
• The official contact for investor relations correspondence is ir@cyclacel.com.

Finance: draft 13-week cash view by Friday.

Cyclacel Pharmaceuticals, Inc. (CYCC) - Canvas Business Model: Channels

You're looking at how Cyclacel Pharmaceuticals, Inc. gets its value propositions-primarily the development of plogosertib-to its stakeholders, which involves clinical partners, investors, and now, surprisingly, a fire safety equipment distribution arm. The channels are a mix of traditional pharma development pathways and a newly integrated commercial/operational channel via a planned acquisition.

For drug candidate testing and development, the channel is the established clinical trial network, though the company is currently focused on advancing an alternative oral formulation of plogosertib. This focus follows the repurchase of related assets from its liquidated UK subsidiary for approximately $0.3 million in cash on March 10, 2025.

Capital infusion relies heavily on the public equity market and strategic financing discussions. Cyclacel Pharmaceuticals, Inc. is actively exploring strategic alternatives, including raising additional capital or pursuing mergers and acquisitions, as its current cash runway was estimated to fund planned expenditure only into the fourth quarter of 2025.

The public equity trading channel is the NASDAQ Capital Market, where the stock trades under CYCC and CYCCP. To maintain compliance and enhance market appeal, the company executed a 15 for 1 reverse stock split on July 7, 2025. Before this action, the market capitalization stood at approximately $5.6 million.

A unique channel involves the planned acquisition of FITTERS Sdn. Bhd., a Malaysia-based company specializing in supplying and trading fire safety equipment. This transaction, structured via an Exchange Agreement with FITTERS Diversified Berhad, will make FITTERS Sdn. Bhd. a wholly-owned subsidiary upon closing. As part of the consideration for this acquisition, Cyclacel Pharmaceuticals, Inc. will pay $1,000,000 or a mutually agreed upon amount at closing.

Here is a quick look at the key financial metrics tied to these operational and capital channels as of mid-2025:

Financial Metric/Activity	Channel Relevance	Amount/Value (as of 2025 data)
Cash and Cash Equivalents (as of June 30, 2025)	Capital Runway/Financing	$4.3 million
Net Cash Used in Operating Activities (Q2 2025)	Operational Burn Rate	$1.1 million
Plogosertib Asset Repurchase Cost	Clinical Development Channel Investment	Approximately $0.3 million
Research and Development Expenses (Q1 2025)	Clinical Trial Network Activity	$0.8 million
Net Loss (Q1 2025)	Financial Health/Investor Relations	$0.1 million
FITTERS Sdn. Bhd. Acquisition Payment	Fire Safety Equipment Channel Integration Cost	$1,000,000 (or mutually agreed amount)
Reverse Stock Split Ratio	Public Equity Trading Channel Maintenance	15 for 1

The shift in focus to plogosertib meant that UK research & development tax credits, which were $1.4 million for Q1 2024, dropped to zero for Q1 2025 due to the subsidiary's liquidation. The company's general and administrative expenses for Q2 2025 were $1.2 million, down from $1.6 million year-over-year for the same period in 2024.

The channels for capital are clearly bifurcated right now:

• Clinical Trial Networks for drug candidate testing and development:
• Repurchase of plogosertib assets for $0.3 million.
• R&D expenses for Q1 2025 were $0.8 million.
• Investment banks and private placements for capital infusion:
• Exploring financing options due to cash runway into Q4 2025.
• NASDAQ Capital Market for public equity trading (CYCC):
• Executed 15 for 1 reverse stock split on July 7, 2025.
• Direct sales and distribution network for fire safety equipment:
• Planned acquisition of FITTERS Sdn. Bhd. involving a $1,000,000 payment.

Cyclacel Pharmaceuticals, Inc. (CYCC) - Canvas Business Model: Customer Segments

You're looking at the core groups Cyclacel Pharmaceuticals, Inc. (CYCC) targets for its clinical assets and capital needs as of late 2025. This isn't about selling widgets; it's about advancing drug candidates and securing the runway to do so.

Oncology and hematology patients (ultimate beneficiaries) represent the end-user for the drug pipeline, primarily focusing on patients with advanced cancers and hematological malignancies where plogosertib, a PLK1 inhibitor, is being evaluated.

Specific patient populations of interest include:

• Patients with solid tumors and hematological malignancies for plogosertib.
• Patients with fibrolamellar carcinoma (FLC), a rare liver cancer where preclinical data suggests sensitivity to plogosertib.
• FLC annual US incidence is estimated at 0.02 per 100,000.
• FLC five-year survival is approximately 30%.
• Patients with CDKN2A and/or CDKN2B abnormalities for the fadraciclib Phase 2 study cohort.

Large institutional and private equity investors are crucial for funding the clinical development, especially given the negative operating cash flow of $3.25M for the period ending July 15, 2025. The company's market capitalization stood at approximately $5.6 million as of July 7, 2025.

Investor activity in the first half of 2025 shows continued interest from sophisticated capital pools:

Investor Group Activity	Time Period	Shares Added/Decreased	Estimated Value
ARMISTICE CAPITAL, LLC (Added)	Q4 2024	435,461 shares (+300.3%)	$163,733
CITADEL ADVISORS LLC (Added)	Q1 2025	51,921 shares (+inf%)	$231,941
POINT72 ASSET MANAGEMENT, L.P. (Added)	Q1 2025	14,375 shares (+1500.5%)	$64,216
XTX TOPCO LTD (Added)	Q1 2025	14,285 shares (+inf%)	$3,988
Institutional Investors Net Change	Q1 2025	9 added, 4 decreased positions	N/A

Capital raising efforts include a $3 million private placement completed in Q2 2025 and a previously announced $25 million PIPE financing. The company's cash and cash equivalents were $4.3 million as of June 30, 2025.

Pharmaceutical companies for potential licensing or co-development are key strategic partners for advancing clinical trials, development, and commercialization. While no specific licensing deals are detailed for 2025, the company did repurchase assets related to plogosertib from Cyclacel Limited for approximately $0.3 million in cash on March 10, 2025, consolidating development focus.

Domestic and international fire safety equipment markets are indirectly relevant through a strategic partner relationship. Cyclacel entered an Exchange Agreement with FITTERS Diversified Berhad, which involves acquiring FITTERS Sdn. Bhd., a Malaysia-based company specializing in supplying and trading various protective and fire safety equipment.

Key terms of the amended agreement with FITTERS Parent include:

• Consideration includes approximately 19.99% of the Company's common stock.
• The Company will pay $1,000,000 or a mutually agreed amount at closing.
• The Final Date under the Exchange Agreement was extended to September 30, 2025.

Finance: draft 13-week cash view by Friday.

Cyclacel Pharmaceuticals, Inc. (CYCC) - Canvas Business Model: Cost Structure

You're looking at the cost structure for Cyclacel Pharmaceuticals, Inc., now operating as Bio Green Med Solution, Inc. following its strategic pivot and acquisition of Fitters Sdn. Bhd. The cost base has clearly shifted away from heavy R&D, reflecting the cessation of the UK subsidiary's operations and the new focus on the fire safety division. Here's the quick math on the major cost drivers from the second quarter of 2025, which sets the stage for late 2025.

The primary operating costs are dominated by the administrative overhead and the remaining, significantly curtailed, research efforts. General and administrative (G&A) expenses for Q2 2025 were reported at $1.2 million. This figure reflects lower operating costs overall, but it was partially offset by specific, one-off charges related to the ongoing corporate changes. To be fair, this G&A number is a significant component of the total burn rate, which resulted in a net loss of $1.3 million for that quarter.

Research and development (R&D) expenses saw a drastic reduction, which is the most significant structural change. For Q2 2025, R&D expenses were only $0.1 million. This massive drop, down from $2.0 million in Q2 2024, is directly tied to the liquidation of the UK subsidiary and the pausing of the transcriptional regulation program, though work on plogosertib continues at a reduced pace.

The newly integrated fire safety product line introduces a new cost category: Costs of Goods Sold (COGS). While the Q2 2025 data doesn't break this out, the subsequent Q3 2025 report gives us a concrete number for this new business segment. Cost of sales related to the sales and distribution of fire safety equipment for the three months ended September 30, 2025, was $64,000. This is a clear indicator of the new, lower-margin, but revenue-generating, cost base from the Fitters acquisition.

Legal and professional fees are a key element within the G&A structure, particularly during this period of corporate restructuring and financing. While a specific line item for these fees isn't isolated in the Q2 2025 reports, we know they were a factor. Specifically, the G&A savings against the prior year were partially offset by 'increased legal fees.' Furthermore, the financing activities themselves involved concrete cash outlays related to the restructuring. For instance, the amended share exchange agreement with FITTERS Diversified Berhad included a cash consideration payment of $1.0 million, which is a direct cost associated with the corporate financing and restructuring effort.

You can see how the cost profile has changed below, comparing the major components from the Q2 2025 period and the new COGS from Q3 2025:

Cost Component	Period	Amount (USD)
General and Administrative (G&A) Expenses	Q2 2025	$1,200,000
Research and Development (R&D) Expenses	Q2 2025	$100,000
Cost of Sales (Fire Safety Equipment)	Q3 2025	$64,000
Cash Consideration for Share Exchange (Restructuring/Financing Related)	Q2/Q3 2025 Activity	$1,000,000
Net Loss	Q2 2025	$1,300,000

The cost structure is now characterized by a relatively fixed G&A base, near-zero R&D, and variable COGS tied to the new product sales. The major non-operating cost impacting cash flow in the period was the $1.0 million cash component of the Fitters acquisition.

• G&A decrease in Q2 2025 was approximately $0.4 million year-over-year.
• R&D expenses decreased by about 95% year-over-year in Q2 2025.
• The company raised $3 million via Series F preferred stock in Q2 2025 to support operations.
• Net cash used in operating activities for Q2 2025 was $1.1 million.

Finance: draft 13-week cash view by Friday.

Cyclacel Pharmaceuticals, Inc. (CYCC) - Canvas Business Model: Revenue Streams

You're looking at the revenue streams for Cyclacel Pharmaceuticals, Inc. during a major transition period, specifically as of late 2025. Honestly, the revenue picture is dominated by financing activities rather than product sales, which is typical for a clinical-stage biotech pivoting its strategy.

The primary source of capital inflow during this time has been equity financing, which is crucial for funding operations when product revenue is absent. You should note the significant financing event that occurred early in the year.

• Equity financing from private placements, such as the \$25 million Private Investment in Public Equity (PIPE) financing executed in February 2025 with Helena Special Opportunities 1 Ltd..
• This \$25 million PIPE allows for controlled stock sales over a 36-month period.
• Additional financing included a \$3.0 million private placement in June 2025.

When we look at operational revenue for the biopharmaceutical segment, the numbers are stark. For the first quarter of 2025, Cyclacel Pharmaceuticals, Inc. reported no product revenue.

Revenue Category (Q1 2025)	Amount (USD)	Notes
Product Sales Revenue	\$0	No product revenue reported for Q1 2025.
Clinical Trial Supply Revenue	\$0	Reported as zero for the three months ended March 31, 2025.

Future revenue streams are now tied to the company's strategic pivot, which includes the acquisition of a fire safety equipment business. Following the Exchange Agreement, the entity is now known as Bio Green Med Solution, Inc., reflecting this diversification.

• Future sales revenue is anticipated from the fire safety equipment division, which is the integration of Fitters Sdn. Bhd., a Malaysia-based group specializing in fire protection products and services.

For the core drug development program, revenue potential remains contingent on external events, as the company is focused solely on plogosertib development.

• Potential milestone payments or licensing revenue from the development of plogosertib, a PLK1 inhibitor, remains a possibility, though no specific amounts were reported as of late 2025.

Finance: draft 13-week cash view by Friday.